Podcasts about sandoz

Theramex is the third UK pharma company to leave PMCPA jurisdiction in three years (Sandoz 2023, Evolus 2024, Theramex 2026). Does that reflect increasing rules, companies avoiding audit, or self-regulation management of issues? Rina & Jean discuss how we got here and what it means for the future of self-regulation.

Wie steht's um deine Altersvorsorge? Kannst du dir jetzt bei Scalable Capital kostenlos ausrechnen. Cerebras startet mit 100 Mrd. $ Bewertung. NVIDIA knackt 5.700 Mrd. $ dank China-Deal. Cisco legt 14% zu trotz Entlassungen. Klarna erstmals profitabel. Stubhub steigt. Ford hyped neues Batterie-Business. Allianz und Siemens solide. CSG will KNDS. China-treffen läuft. Sandoz (WKN: A3ETYB) kopiert die größten Blockbuster der Pharmabranche. Biosimilars wachsen mit 13%, Semaglutid steht auf der Liste. Aktie 90% im Plus, KGV bei 20. Chance oder schon eingepreist? Markel (WKN: 885036) will das nächste Berkshire sein. Aktivist Jana Partners fordert den Verkauf der Ventures-Sparte. CEO lehnt ab. Aktie nur 30% über Buchwert, Management sieht 60% Upside. Diesen Podcast vom 15.05.2026, 3:00 Uhr stellt dir die Podstars GmbH (Noah Leidinger) zur Verfügung. Learn more about your ad choices. Visit megaphone.fm/adchoices

Drei Aktien stehen im Fokus: Sandoz mit möglicher Übernahmefantasie, Diamondback Energy als fokussierter US-Ölwert und TotalEnergies als globaler Energiekonzern mit Dividendenprofil. Im Zentrum stehen Bewertung, operative Entwicklung, Ölpreisrisiken und die Frage, wo noch verstecktes Potenzial liegen könnte.

Ein Fünftel der Flüge über die Nebenpiste am Euroairport musste bisher umgeleitet oder annulliert werden. Grund ist der Wind, der stark wehte in den letzten Tagen. Die Hauptpiste am Flughafen ist derzeit wegen Sanierungsarbeiten gesperrt. Ausserdem Thema: · Basler FDP wählt Tamara Hunziker als Präsidentin · Zahlen von Straumann und Sandoz

Heb je je ooit afgevraagd wat er precies gebeurt in je brein als de "ego-machine" even wordt uitgezet? In de nieuwste Wetenschap Op Woensdag (#361) duiken Istvan, Mario en Minya diep in de fascinerende wereld van psychedelica. Van de ontdekking van LSD op een Zwitserse fiets tot de duistere experimenten van de CIA (MK Ultra), en van het genezen van hardnekkige depressies tot het "horen van kleuren". We bespreken het allemaal!

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. This week, we delve into a series of compelling stories that are shaping the future of drug development, therapeutic innovation, and patient care. The gene therapy sector is currently under the spotlight, with Johnson & Johnson handing back the rights to botaretigene sparoparvovec to MeiraGTx following a phase 3 trial failure. This underscores the inherent challenges in developing treatments for rare diseases, where the stakes are high and financial consequences significant. Despite this setback, optimism persists in the industry. Ocugen, for instance, is forging ahead with plans for multiple gene therapy approvals in the coming years. Their strategy focuses on broadening access to these treatments, reflecting a shift towards achieving commercial scalability alongside technical innovation. The funding landscape for biotech startups is experiencing a downturn, with early-stage financing at its lowest post-pandemic levels. This poses substantial challenges to innovation-driven companies that rely on robust funding environments to propel their research forward. However, not all news is bleak; strategic partnerships are proving to be a valuable avenue for growth. Aligos Therapeutics' collaboration with Amoytop in China exemplifies how geographic strategies can unlock value and optimize resources across regions. In Alzheimer's research, anti-amyloid drugs are under renewed scrutiny. Despite FDA approvals, their efficacy has come into question, shedding light on the complexities of translating mechanistic hypotheses into clinical success. This ongoing debate highlights the necessity for innovative approaches that offer more definitive clinical benefits. On the regulatory front, significant changes are underway as seen with the FDA's reclassification of peptides ahead of an advisory committee meeting. This move indicates a commitment to maintaining rigorous safety and efficacy standards amid evolving scientific practices. Meanwhile, Eli Lilly's proactive measures in addressing FDA safety concerns for its obesity drug Foundayo demonstrate how companies are navigating regulatory landscapes to expand therapeutic indications while ensuring compliance. Adaptive trial designs are making headway in oncology, offering a promising method to accelerate cancer drug approvals through real-time data analysis. These flexible methodologies signify a shift towards more dynamic regulatory approaches that can expedite patient access to novel therapies. Spain's initiative to integrate its biotech sector with Boston's life sciences ecosystem through a $200 million venture capital fund represents a strategic push towards fostering innovation and growth. This cross-continental collaboration aims to leverage Boston's advanced infrastructure and expertise, enhancing Spanish biotechs' global competitiveness. In business news, Beeline Medicines' impressive $300 million Series A funding highlights a trend towards substantial investments in emerging biotech firms with promising drug candidates. By licensing compounds from Bristol Myers Squibb, Beeline is poised to make significant strides in autoimmune therapeutics. Sandoz's agreement with Rwanda marks an important step towards addressing healthcare needs in Africa by providing essential medicines for infectious diseases and oncology. This partnership underscores the growing importance of global collaborations in enhancing healthcare accessibility. The acquisition of QIMR Berghofer's epigenetic drug discovery platform by Kazia Therapeutics reflects the increasing interest in leveraging AI/ML-driven approaches within oncology and drug discovery sectors. Such strategic expansions are emblematic of broader industry trends towards precision medicine. In an era where technological innovations redefine Support the show

Breakout: Developing Ministry that Connects with Your Community with Dwight Sandoz on Friday, April 17, at 4:30 pm at the EQUIP Conference The post EQUIP Conference 2026 – April 17th Breakout with Dwight Sandoz appeared first on MDC.

On the April 3 episode of Friday LIVE, we're broadcasting from the Mill in Lincoln's historic Haymarket. Host Genevieve Randall will have lively conversations with: Author Alan Bartels, discussing his new book featuring stories about the Sandhills in Nebraska (0:30); Carrie Brown and Karim Muasher, co-artistic directors for the world premiere of Capital City at the Lied Center for the Performing Arts (11:06); Morrie Enders, executive director of the Lincoln Community Playhouse(23:29); Scott Kirby, sharing his traveling Main Street Souvenirs show coming to Red Cloud (46:12). The episode will also feature more poetry by Nathan Ertzner (33:03) and a movie review of Billy Preston: That's The Way God Planned It by Kwakiutl Dreher (40:52).

On the April 3 episode of Friday LIVE, we're broadcasting from the Mill in Lincoln's historic Haymarket. Host Genevieve Randall will have lively conversations with: Author Alan Bartels, discussing his new book featuring stories about the Sandhills in Nebraska (0:30); Carrie Brown and Karim Muasher, co-artistic directors for the world premiere of Capital City at the Lied Center for the Performing Arts (11:06); Morrie Enders, executive director of the Lincoln Community Playhouse(23:29); Scott Kirby, sharing his traveling Main Street Souvenirs show coming to Red Cloud (46:12). The episode will also feature more poetry by Nathan Ertzner (33:03) and a movie review of Billy Preston: That's The Way God Planned It by Kwakiutl Dreher (40:52).

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we explore the latest news and trends shaping this dynamic industry.Significant strides have been made recently, particularly with the FDA's approval of J&J and Protagonist Therapeutics' novel psoriasis medication, Icotyde. This once-daily oral treatment could disrupt a market dominated by injectable therapies. The convenience of oral administration is likely to improve patient compliance and drive substantial sales, marking a pivotal moment in psoriasis treatment. The Phase 3 ICONIC trial demonstrated substantial efficacy over existing treatments like Bristol Myers Squibb's Sotyktu. This trend towards more patient-friendly options is indicative of a broader industry shift and signifies Protagonist's entry into competitive immunology markets.Turning to biosimilars, Sandoz has expanded its partnership with Samsung Bioepis to commercialize up to five biosimilars, including a version of Takeda's Entyvio. This collaboration highlights the industry's growing reliance on biosimilars as affordable alternatives to branded biologics. Amidst pricing pressures and a global demand for accessible medications, such strategies are becoming increasingly vital.In an ambitious venture, TerraPower Isotopes, backed by the Gates Foundation, is investing $450 million in a plant for producing actinium-225, a rare isotope used in radiopharmaceuticals. This move positions TerraPower as a leader in supplying crucial ingredients for targeted cancer therapies—an area that promises advancements in precision medicine by offering targeted treatments with fewer side effects.Regulatory landscapes are evolving too, with the FDA and NIH committing $150 million towards alternatives to animal testing in drug development. This initiative emphasizes ethical scientific practices and leverages innovative technologies like organ-on-chip systems. Such regulatory support is essential for speeding up drug development while ensuring safety standards remain high.Stem cell therapy also sees promising developments with Aspen Neuroscience's treatment for Parkinson's disease. After one year, all treated patients showed symptom improvement, paving the way for pivotal Phase 3 trials. These results underscore the transformative potential of regenerative medicine in tackling neurodegenerative disorders.As the industry evolves, it faces challenges such as looming patent expirations and intensified competition. These pressures are prompting companies to innovate and reconsider strategies for existing product lines. In response to these challenges, strategic realignments are becoming more common.Meanwhile, Indiana's plan to create 100,000 jobs through a $1 billion strategy highlights regional efforts to establish hubs for life sciences innovation, illustrating the broader economic impact of the biopharma sector.In parallel news, Xaira Therapeutics has raised an impressive $1 billion to leverage AI for drug discovery in inflammatory and immunological research. This underscores growing reliance on AI technologies to accelerate drug development timelines. Crossbow Therapeutics reached a significant milestone by securing $77 million in Series B funding to advance its T-cell engager technology—a promising approach in immuno-oncology that harnesses the immune system against cancer cells.Despite these advancements, economic pressures continue to challenge some companies. Layoffs at Gossamer Bio and Bicycle Therapeutics highlight sector volatility and the need for strategic adaptability. Corporate governance remains under scrutiny as Moderna's CEO compensation package reveals executive priorities amidst revenue shortfalls. Meanwhile, GSK faces criticism over its management practices concerning Flovent, which raises ethical concerns about pricing strategies.In cardiovascular care, Support the show

What does it take to get a life-changing medicine from regulatory approval to the patient who needs it? Isabell Remus, Global Head of Biosimilars at Sandoz, reveals why being approved and affordable isn't enough – and how the biosimilar industry learned that trust and education must come before market access. With $320 billion in biologic medicines losing patent exclusivity over the next decade, she explores the strategic complexities of launching at the exact moment a patent expires, the role of diversified manufacturing in strengthening supply chain resilience, and why expanding access to essential medications requires both purpose and commercial viability. An eye-opening conversation on making affordable healthcare a reality for millions of patients worldwide.

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we delve into a series of significant advancements and strategic shifts currently shaping the landscape of these industries.To start, let's discuss a remarkable development in therapeutic treatments. UCB's Bimzelx has demonstrated superior efficacy over AbbVie's Skyrizi in treating psoriatic arthritis, as revealed by a head-to-head phase 3b clinical trial. This finding not only extends UCB's winning streak in psoriasis treatment but also positions Bimzelx as a competitive alternative in the immunology sector. The implications of this are profound, potentially influencing prescribing patterns and improving patient outcomes by offering an effective alternative for those with psoriatic conditions.In manufacturing news, Eli Lilly is making waves with its substantial $3 billion investment aimed at enhancing the global supply chain for Orforglipron, their oral GLP-1 receptor agonist. This move highlights a growing demand for GLP-1 therapies, crucial for managing type 2 diabetes and obesity. The strategic focus on oral therapies reflects a broader industry trend towards improving patient compliance compared to injectable alternatives, underscoring the importance of such innovative treatments in addressing widespread health issues. Additionally, Eli Lilly's commitment to investing $500 million into South Korea's biopharmaceutical sector signals the country's rising status as a hub for biopharmaceutical innovation and development, likely fostering collaborations and expediting novel therapeutics' development.Economically, there's compelling evidence of the impact public funding has on scientific advancement. A recent report by United for Medical Research revealed that National Institutes of Health (NIH) grants generated $94.15 billion in economic activity in 2025, supporting nearly 391,000 jobs. This underscores the dual role of public funding in advancing biomedical research and stimulating economic growth.On the regulatory front, Sandoz is making a strategic move to establish a standalone unit dedicated to biosimilars. As we enter what Sandoz describes as a 'golden decade' of patent expirations, this realignment reflects anticipation of expansion opportunities within the biosimilars market. Such preparations suggest increased competition and potentially more affordable biologic therapy options as major drugs lose patent protection.Technological advancements are further shaping industry operations. BD's partnership with Sinteco to automate pharmacy logistics in Europe is part of a broader push to integrate robotics into healthcare processes. This aligns with digital transformation trends across the sector aimed at improving efficiency and reducing human error. Meanwhile, Medtronic's former diabetes division Minimed has achieved European approval for its 780G insulin pump system, which integrates with Abbott's continuous glucose monitor (CGM). This approval is noteworthy for enhancing diabetes management through automation of insulin delivery based on real-time glucose monitoring, representing a significant step forward in closed-loop systems.A notable technological initiative comes from ARPA-H with their program focused on developing wearable biosensors under the Delphi initiative. These sensors aim to enhance personal health monitoring capabilities across various devices, aligning with trends towards personalized medicine and digital health technologies.Despite these positive strides, challenges persist. The closure of F5 Therapeutics highlights early-stage biotech struggles amid competitive pressures. Regulatory setbacks also continue to pose challenges; Novo Nordisk recently received an FDA warning letter following inspection issues at its U.S. headquarters.Collectively, these trends reflect an industry resiliently pursuSupport the show

Rediffusion. Découvrez un récit d'emprise familiale. Dans des immeubles du XIe, XIIe et XXe arrondissements, une étrange communauté s'épanouit depuis plus de deux cent ans. Des cousins qui se marient entre eux et qui ne se mélangent pas. Ce n'est pas vraiment une secte mais plutôt une organisation secrète, une société dans la société, comparable à aucune autre. On les surnomme “La Famille”. Tout au long des 4 épisodes, Caroline Nogueras sera accompagnée de la journaliste Suzanne Privat, autrice du livre La Famille, itinéraire d'un secret paru aux éditions Points. Mon oncle Auguste La famille se réunit autour d'une chrétienté en marge de l'Eglise, régi par l'austérité et la discrétion. Depuis sa création en 1819, d'autres patronymes sont venus grossir les rangs. Les Havet et Thibout ont été rejoints par les Sanglier, Déchelette, Sandoz, Maître, Pulin et Fert. Au début du XXeme siècle, un homme, Paul Augustin Thibout, descendant direct des fondateurs, va durcir le ton et cadrer les troupes. Un podcast Bababam Originals Ecriture : Capucine Lebot Voix : Caroline Nogueras Learn more about your ad choices. Visit megaphone.fm/adchoices

„3 rein, 3 raus“ - Rebalancing im BX Musterportfolio: Siemens Energy & Sandoz neu im BX Musterportfolio. Im BX Morningcall diskutieren Investment-Stratege François Bloch und Olivia Hähnel (BX Swiss) ausgewählte Top-Aktienwerte aus dem BX Musterportfolio, inklusive Rebalancing-Entscheid. NEU✅ Legrand - FR0010307819 NEU✅ Infineon - DE0006231004 NEU✅ Schneider Electric - FR0000121972 3 Aktien verlassen das BX Musterportfolio: ❌ Broadcom Inc US11135F1012 ❌ Wells Fargo & Co US9497461015 ❌ Alphabet A (stimmrecht) US02079K3059

Cour Suprême contre Trump. Tarifs douaniers bricolés à la tronçonneuse. Private credit qui commence à tousser. Nvidia qui pulvérise les attentes… sans réussir à enflammer le marché. Et puis le week-end arrive. Attaque sur l'Iran. Détroit d'Ormuz fermé. Pétrole sous tension. Et les experts de X qui annoncent le bain de sang pour lundi matin. On connaît la musique : ➡️ pétrole qui monte ➡️ inflation qui menace ➡️ baisses de taux qui s'évaporent ➡️ et tout le monde qui crie à la récession La vraie question n'est pas “est-ce que ça va baisser ?” La vraie question, c'est : est-ce que l'on est (encore) face à un moment où il faut acheter au son du canon ? Dans cette vidéo, on parle : du choc géopolitique et de son impact sur les marchés du pétrole et du risque d'inflation de la psychologie des investisseurs en période de guerre de ce que l'histoire nous a appris (1941, 1991, 2003, 2022…) et surtout… des opportunités qui naissent quand tout le monde panique Parce que les marchés ne réagissent pas à la morale. Ils réagissent à la peur. Et souvent, les meilleures décisions se prennent quand le bruit est maximal.

In der Pharmaindustrie laufen in den nächsten 10 Jahren Patente im Wert von über 650 Mrd. US-Dollar aus. Profiteure sind Hersteller von Nachahmer-Produkten wie Sandoz. Laut der Produkte-Leiterin Rebecca Guntern hat Sandoz mit 27 Biosimilars eine führende Pipeline in diesem margenstarken Segment. SMI -0.1%

Episode 359 features Hannah Sandoz, a performer-composer out of Chicago. In the interview we talked a lot about DIY touring, songwriting, and the ChiTown music scene. I featured “dominator1” on this episode, and if you like it you can stream it wherever you listen to music.    Hann Sandoz creates music that holds you while you cry, weaving tender lyrics with lush, intimate arrangements for guitar, vocals, and laptop. After first writing songs as a teen using scrappy recording techniques and candid, emotionally raw lyrics, they went on to study classical composition and production at the Oberlin Conservatory. That background shaped a reverent creative practice centered on tenderness, shared experience, and emotional memory.   We also dive into their latest release, MF / HS, which came out in October 2025, four years after relocating to Chicago. To support the record, Hann hit the road for a true DIY run, touring 6,000 miles in just two weeks across the West Coast, playing independent venues like Junior High in LA and Kilowatt in San Francisco. With ethereal vocals and gauzy, rural-tinged instrumentals that will resonate with fans of Adrianne Lenker, Grouper, and Animal Collective, this is a conversation you do not want to miss.   Please follow, rate, or review the podcast wherever you are streaming if you'd like to help us out.  -- Part-Time Rockstar Productions is available in the DMV for music videos and live filming.     

„2 rein, 2 raus“ - Rebalancing im BX Musterportfolio: Siemens Energy & Sandoz neu im BX Musterportfolio. Im BX Morningcall diskutieren Investment-Stratege François Bloch und Olivia Hähnel (BX Swiss) ausgewählte Top-Aktienwerte aus dem BX Musterportfolio, inklusive Rebalancing-Entscheid. NEU✅ Sandoz - CH1243598427 NEU✅ Siemens Energy - DE000ENER6Y0 Aus dem Musterportfolio: Howmet Aerospace - US4432011082 2 Aktien verlassen das BX Musterportfolio: ❌ Dollarama CA25675T1075 ❌ JPMorgan Chase & Co US46625H1005

In today's increasingly globalized financial markets, international investor engagement is more important than ever. In this episode of Winning IR, Mark Fasken sits down with Craig Marks, Head of Investor Relations at Sandoz, to discuss the practical realities of planning and executing successful international roadshows. Drawing on two decades of experience across major pharma companies, Craig shares his hands-on insights for navigating logistics, targeting the right investors, and maximizing the impact of every meeting. Listen to the full episode to learn more about: How to tailor outreach strategies for different regions and investor types The importance of detailed logistics planning, from city-by-city travel tips to private lunches Approaches for targeting, engaging, and policing brokers to ensure the right investors are reached Myths and realities about regional differences in investor engagement and conversation style The evolving role of ESG in investor relations and why its focus may be shifting Building long-term relationships by revisiting key markets and leveraging local knowledge Craig's personal tips for making investor meetings productive and memorable   Winning IR is brought to you by Irwin. For more winning ideas, subscribe to Winning IR wherever you get your podcasts.For more information, visit getirwin.com/winning-ir

Erhan Eskicumalı ‘nın hazırlayıp sunduğu Makine Emniyeti ve Güvenliği programına Sandoz Ülke Kıdemli İş Sağlığı Güvenliği ve Çevre Yöneticisi Banu Özlem Kuralay konuk oldu.

Erhan Eskicumalı ‘nın hazırlayıp sunduğu Makine Emniyeti ve Güvenliği programına Sandoz Ülke Kıdemli İş Sağlığı Güvenliği ve Çevre Yöneticisi Banu Özlem Kuralay konuk oldu.

En rénovant son manoir breton, François découvre 239 pièces d'or dissimulées dans les murs, une trouvaille exceptionnelle qui va bouleverser sa vie. Le commissaire-priseur Aymeric Rouillac, spécialiste des trésors du quotidien, nous expliquera comment reconnaître, authentifier et révéler la valeur d'un objet trouvé chez soi. Philippe, qui ouvre par hasard un vieux coffre-fort acheté en brocante et y découvre des lettres de 1945, des décorations militaires et les testaments d'un couple disparu : un trésor intime qu'il restituera aux descendants de cette famille. Au téléphone également, Brigitte, nous parle de son bronze posé dans son salon depuis quarante ans et s'avère être une œuvre rare de Sandoz, adjugée 190 000 euros. Hébergé par Audiomeans. Visitez audiomeans.fr/politique-de-confidentialite pour plus d'informations.

Richard Saynor reflects on what it takes for leaders to combine accountability, clear decision-making, and the humility to change course. Hosted on Acast. See acast.com/privacy for more information.

24-3116_24-3146_Sandoz Inc v. United Therapeutics Corporationetal.

Entretien mené par Laurent Evrard « Violenté jusqu'à ce que je m'aligne sur la vibration nouvelle. » Henri Michaux Muriel Pic propose un texte inédit sur les expérimentations de drogues par Henri Michaux à l'époque où l'on inventait les médicaments psychotropes. Henri Michaux (1899-1984), écrivain et peintre, participe à partir de 1955 aux recherches sur les hallucinogènes conduites à l'échelle mondiale. Pendant des années, il va expérimenter diverses substances – haschich, mescaline, champignons, LSD – sous le contrôle et en collaboration avec l'hôpital Sainte-Anne, le Muséum d'histoire naturelle de Paris ou encore avec les laboratoires pharmaceutiques suisses Sandoz, qui produisent les molécules utilisées à des fins cliniques et thérapeutiques. La révolution psychopharmacologique aboutit à l'invention de la médication psychotrope et au contrôle chimique du comportement. Cet événement majeur dans l'histoire des sciences est raconté ici du point de vue d'un artiste qui en fut à la fois le témoin et l'acteur. Muriel Pic se fonde sur les archives inédites des expérimentations sous drogue de Michaux : des notes d'auto-observation d'un incomparable éclat poétique. À partir de ce matériau fascinant, l'ouvrage replace pour la première fois l'œuvre de Michaux dans son contexte en rappelant que ses textes et dessins nés de la folie volontaire ont d'abord été considérés par les médecins comme des documents scientifiques sur l'hallucination. Cet ouvrage est richement illustré des dessins de Michaux créés sous influence et de nombreux documents issus de ses « archives de la drogue ». Avec le soutien de Pro Helvetia. À lire – Muriel Pic, Leçons de possession. Les archives de la drogue d'Henri Michaux, éditions Macula, 2025.

The manufacturer of Estradot patches says its actively investigating reports that some of the patches are faulty - but so far testing hasn't found any defects. Women have been having problems with the oestrogen patches not sticking properly or not working. Sandoz has told RNZ it's received about 50 complaints, Medsafe says it's received 149 complaints, but there wasn't enough evidence to warrant a recall. Ministry of Health Clinical Chief Advisor Anna Skinner spoke to Ingrid Hipkiss.

Javnost težko pride do podatka o izvoru sestavin za določeno zdravilo. Na katerih področjih imata Kitajska in Indija že tako rekoč monopol?V farmacevtski industriji se vrti veliko denarja – posel je posel. Leta 2023 so tako farmacevtska podjetja in njihovi partnerji na globalni ravni zabeležili več kot 1.600 milijard ameriških dolarjev prihodka. Za primerjavo: to je približno toliko, kot je znašal celoletni bruto domači proizvod Avstralije, Španije ali Mehike. V želji po optimizaciji proizvodnje in maksimiranju dobička farmacevtske družbe zdravil ne proizvajajo več na eni sami lokaciji, ampak svoje priložnosti iščejo na globalnem trgu. Pogosto se zgodi, da zdravilo, preden pride do bolnice ali bolnika v Evropi ali ZDA, prepotuje polovico sveta. Nemška profesorica Ulrike Holzgrabe ocenjuje, da se približno 70 odstotkov aktivnih sestavin proizvede na Kitajskem in v Indiji, približno 25 v Evropi, preostalih 5 odstotkov pa v ZDA. Kakšno tveganje predstavlja ta izpostavljenost in odvisnost od Kitajske in Indije za največja zahodna farmacevtska podjetja in ne nazadnje tudi za zahodne države same? Ali zato vedno pogosteje prihaja do motenj v preskrbi z zdravili? Kje so največja ozka grla? Kakšno vlogo ima pri tem dobiček? Odgovori v Intelekti. Sodelujejo: prof. dr. Ulrike Holzgrabe (Univerza v Würzburgu), direktor oskrbe Miha Bahar (Lek, Sandoz) in prof. dr. Rok Dreu (Fakulteta za farmacijo v Ljubljani). Foto: BoBo

In this episode of SCW for Pharma host Evren Ozkaya welcomes Katja Lumbar Globocnik, Head of U.S. Supply Chain at Exeltis and Xiromed, subsidiaries of Insud Pharma. Katja brings decades of experience across global pharmaceutical supply chains, from her early days in Europe with companies like Novartis and Sandoz to leading countless generic product launches at Teva in the United States.Evren and Katja open their discussion by comparing the dynamics of large versus small-to-mid-sized pharma companies. Katja explains how larger organizations, while rich in structure and learning opportunities, can be slowed by bureaucracy. In contrast, smaller companies operate with greater agility, allowing individuals to take broader ownership of decisions and execution. This leaner environment, she notes, cultivates problem solvers.The conversation then turns to digitalization and system maturity. Contrary to expectations, Katja argues that size doesn't guarantee sophistication. Many large companies still rely on traditional operations, while smaller firms like Insud Pharma have adopted advanced technologies, including AI-driven analytics and automation. These tools, she explains, are transforming supply chains by accelerating decision-making, enabling real-time visibility, and automating repetitive tasks.Evren and Katja also examine the management of operational excellence in multi-site environments. Katja sees clear value in driving OpEx globally, while acknowledging the growing trend toward regionalization. Together, they emphasize the importance of balancing standardization with local flexibility—especially as cloud-based systems make real-time benchmarking and performance tracking across sites possible.When discussing product launches, Katja highlights the excitement and challenges of bringing generic medicines to market. Success, she says, depends on teamwork, scenario planning, and calm risk assessment—particularly in the U.S., where speed to market is critical.Finally, the discussion circles back to digital transformation at manufacturing sites. Katja identifies alignment, investment constraints, and resistance to transparency as common barriers. Still, she believes progress is inevitable, led by plant leaders who take a holistic view, embrace visibility, and see weaknesses as opportunities for improvement.Evren closes by asking Katja what advice she would give her younger self. Her answer is simple and powerful: “Be fearless. Learn as much as you can. Go for it until someone stops you.”

In this episode, Barb and Landa dive into "Pleasure Activism" by adrienne maree brown—a powerful collection of essays exploring the politics of feeling good. Join us as we unpack how pleasure, sex, and sexuality intersect with community, disability justice, and personal empowerment. We get PASSIONATE about this book today, and we are pleased to share it with y'all!Find Pleasure Activism HERE!RESOURCES AND LINKS:adrienne maree brown https://adriennemareebrown.net/Rest is Resistance- Tricia Hersey http://www.triciahersey.com/⁠ The Will to Change - bell hooks Laziness Does Not Exist- Dr. Devon PriceBeyond “Yes Means Yes”: A Behavioral Conceptualization of Affirmative Sexual Consent - Emily Sandoz and the Louisiana Contextual Science Research Group (note from Barb: DEEPEST APOLOGIES to Dr. Sandoz for forgetting everything about you and your incredible lab!!!)

Dr. Monty Pal and Dr. Matteo Lambertini discuss a compelling global study on the clinical behavior of breast cancer in young BRCA1 and BRCA2 carriers, the association of pre-diagnostic awareness of BRCA status with prognosis, and the importance of identifying healthy people who are at risk of carrying the BRCA1/2 pathogenic variants. TRANSCRIPT Dr. Monty Pal: Well, hello everyone, and welcome to the ASCO Daily News Podcast. I'm your host, Dr. Monty Pal. I'm a medical oncologist, professor, and vice chair of medical oncology at the City of Hope Comprehensive Cancer Center in Los Angeles. Now, when we think about genetic testing, whether for patients diagnosed with breast cancer or for other family members of them, it seems to be widely underutilized. Today, we're going to be discussing a recently published study in the Journal of Clinical Oncology that reported on the clinical behavior of breast cancer and specifically young BRCA1 and BRCA2 carriers, and the association of pre-diagnostic awareness of BRCA status with prognosis. I thought this was just a fascinating piece, and I honestly couldn't wait to have this conversation. It's a really compelling paper that highlights the importance of identifying healthy people who are at risk of carrying the BRCA1/2 pathogenic variants, and really the need for genetic counseling and testing to inform people about early detection that could lead to a better prognosis. I'm really delighted to welcome the study's lead author, Dr. Matteo Lambertini. He really needs no introduction. He's very well known in the breast cancer world for his amazing contributions to fertility in the context of breast cancer, to pregnancy in the context of breast cancer, and genetic testing. He's an associate professor at the University of Genova, and a breast cancer medical oncologist at the San Martino Polyclinic Hospital in Genova, Italy.  Dr. Lambertini, thank you so much for joining us today. Dr. Matteo Lambertini: Thank you very much, Dr. Pal. It's a great pleasure. Dr. Monty Pal: Oh, thanks. And just FYI, if you're listening in and you want to hear our disclosures, they're all listed at the transcript of this podcast.  So, I poured through this paper [Clinical Behavior of Breast Cancer in Young BRCA Carriers and Prediagnostic Awareness of Germline BRCA Status] yesterday, Dr. Lambertini, and first of all, congratulations on this study. This was a huge international multicenter effort, 4,752 patients. How did you pool all these patients with young breast cancer? Dr. Matteo Lambertini: Thanks a lot for the question. Yes, this was an effort made by several centers all over the world. The main idea behind the creation of this network that we have named as BRCA BCY Collaboration, was to get as many data as possible in a sort of niche patient population in the breast cancer field, meaning women diagnosed with breast cancer at the age of 40 years or younger, and all of them being BRCA carriers. We know that around, in the Western world, around 5% of breast cancer cases are being diagnosed under the age of 40 years, and among them around 10-15% are BRCA carriers. So, I would say it's a relatively rare patient population where we did not have a lot of evidence to support our choices in terms of counseling on treatment, prevention, and oncofertility as well. That was the idea behind the creation of this network that includes many centers. Dr. Monty Pal: Yeah. You know, what's so interesting about this is that you sort of draw this line between patients who have BRCA testing at the time of diagnosis and then BRCA testing earlier in their course and then leading to a diagnosis perhaps. And I think that's where really sort of the dichotomy in outcome sits. Can you maybe elaborate on this and tell us about timing of genetic testing in this study and what that meant ultimately in terms of prognosis? Dr. Matteo Lambertini: In this specific analysis from this large network, including almost 5,000 women with breast cancer diagnosed at the age of 40 years or younger and being a BRCA carrier, we looked specifically into the timing of genetic testing because this is a retrospective study and the criteria for inclusion are those that I have just mentioned, so diagnosis at a young age plus carrying germline BRCA pathogenic or likely pathogenic variant. In this analysis, we have looked into the time the patient has got the genetic testing and particular we focused on two populations: those that were diagnosed, knowing already to be a BRCA carrier, and those that got tested after being diagnosed with breast cancer. And the main findings from this analysis have been that knowing to be a BRCA carrier was associated with a lower stage at the time of diagnosis, meaning more T1 tumors, so a tumor less than 2 cm, more node-negative disease, and this translated into less aggressive treatment, so less often axillary dissection, less often use of chemotherapy and anthracycline-based chemotherapy. And even more importantly, we have seen a better overall survival for those patients that were diagnosed already knowing to be BRCA carriers as compared to those tested after breast cancer diagnosis. These results after adjusting for all the confounding, stage, treatment and so on, there was not significant anymore, meaning that it's not the timing of test per se that is probably leading to a better survival, but it is the fact that knowing to be a BRCA carrier would likely translate into having access to all the preventive measures that we have in this setting and this will translate into an overall survival benefit, so in terms of saving more lives in young BRCA carriers. Dr. Monty Pal: I think it's such an important point, and it's one that I think might sound implicit, right, but it needs to be proven, I think, through a study like this. You know, the fact that finding this early, identifying the mutation, doing enhanced screening, and so forth, is really going to lead to superior clinical outcomes. One of the things that I think many people puzzle over, including myself, is what to do? I personally occasionally will see BRCA altered patients in the context of prostate cancer. But that's a very different population of individuals, right? Typically older men. In young females with BRCA mutation, I guess there's a specific set of considerations around reproductive health. You'd already highlighted preventive strategies, but what sorts of things should we be talking about in the clinics once a patient's diagnosed and once perhaps their breast cancer diagnosis is established? Dr. Matteo Lambertini: Yes, exactly. Knowing to be a BRCA carrier has a lot of implications from prevention to treatment to survivorship issues including reproductive counseling. And this is important not only for the patient that has been diagnosed with breast cancer but also for all the family members that will get tested and maybe identify with this sort of genetic alteration before diagnosis of cancer. Why this is important is because we have access to very effective preventive measures, a few examples: MRI screening, which starts at a very young age and normally young women don't have an effective screening strategy outside the BRCA field. Also, primary preventive measures, for example, risk-reducing surgery. These women are known to have a high risk of breast cancer and high risk of ovarian cancer. So the guidelines are suggesting to undergo risk-reducing salpingo-oophorectomy at a young age, so 35 to 40 years in BRCA1 carrier, 40 to 45 years in BRCA2 carrier. And also risk-reducing mastectomy should be discussed because it is a very effective way to prevent the occurrence of breast cancer. And in some situations, including the setting that we are talking about, so young women with breast cancer, BRCA carrier, also risk-reducing mastectomy has shown to improve overall survival.  On the other side, once diagnosed with breast cancer, nowadays knowing to be or not a BRCA carrier can make a difference in terms of treatment. We have PARP inhibitors in the early setting, in the adjuvant setting as well as in the metastatic setting. And in terms of survivorship implication, one of the critical aspects for young women is the oncofertility care which is even more complicated when we talk about BRCA carriers that are women candidates for gynecological surgery at a very young age. So this sort of counseling is even more complicated. Dr. Monty Pal: One of the other things, and this is subtle in your paper and I hope you don't mind me bringing it up, is the difference between BRCA1 and BRCA2. It really got me thinking about that because there are differences in phenotype and manifestation. Do you mind just expanding on that a little bit for the audience because I think that's a really important reminder that you brought up in the discussion? Dr. Matteo Lambertini: The difference between BRCA1 and BRCA2 carriers has been known that there are different phenotypes of breast cancer that are more often diagnosed in these two different populations. Normally BRCA1 carriers have a higher likelihood to develop a triple negative breast cancer as compared to BRCA2 carriers, more likely to develop a hormone receptor-positive HER2-negative disease. In this study, again, a specific population of young women with breast cancer, we have seen the same findings, mostly triple negative disease in BRCA1 carrier, mostly luminal-like disease in BRCA2 carrier. But what's novel or interesting from this study is to look also at the age at the time of diagnosis of this disease. And particularly in BRCA1 carriers, we should be sort of more careful about diagnosis of breast cancer and also other primary tumors including ovarian cancer because the risk of developing these malignancies is higher even at a younger age as compared to BRCA2 carriers. And this has implications also in the primary and secondary prevention that we were talking about earlier. Dr. Monty Pal: Oh, interesting. I guess the fundamental question then from your paper becomes, how do we get at the right patients for screening for BRCA1 and BRCA2? And I realize our audience here is largely oncologists who are going to be listening to this podcast, oncology providers, MDs, nurses, etc. But maybe speak for a moment to the general practitioner. Are there things that, for instance, a general practitioner should be looking for to say, “Wait a minute, this patient's high risk, we should consider BRCA1, BRCA2 testing or germline screening”? Dr. Matteo Lambertini: Yes, it's a very important question for the breast cancer community. After the updated ASCO guideline, the counseling is way easier because right now the age cutoff goes up to 65 years, meaning that all the patients diagnosed with breast cancer below the age of 65 years should be tested these days. And then above the age of 65, there are different criteria like triple-negative disease or family history. From a general practitioner standpoint, it's of course a bit more difficult, but knowing particularly the family history of the person that they have in front will be crucial to know if there are cases of breast cancer diagnosed at a young age, maybe triple-negative cases, knowing cases of ovarian cancer in first-degree relatives or pancreatic cancer in first-degree relatives, and of course cases of prostate cancer as well. So, I would say probably mostly the family side will be important from a general practitioner perspective.  From an oncology one, the other point that I think is important to stress also based on the data that we have shown in this publication is that having a case of breast cancer known to carry a BRCA pathogenic or likely pathogenic variant. It means that all the people around this case should get tested and if found to be BRCA carrier and healthy carrier, these people should also undergo the primary and secondary prevention strategies because this is very critical also to improve their outcomes and try to avoid the developing of breast or ovarian cancer, but also in the case of diagnosis of this disease, a diagnosis at an earlier stage, as we have seen in this paper. Dr. Monty Pal: Brilliant. I'm going to diverge from our list of questions here and close by asking a question that I have at the top of my mind. You're very young. I know our podcast listeners can't see you, but you're very, very young. Dr. Matteo Lambertini: Thank you. Thank you for that. Not so young but yeah. Dr. Monty Pal: You have nearly 300 papers. Your H-index is 67. You've already made these seminal contributions, as I outlined it from the outset, regarding fertility, regarding use of GnRH analogs, regarding pregnancy and breast cancer. What are you studying now? What are you really excited about right now that you're doing that you think might potentially be practice changing? Give us a little teaser. Dr. Matteo Lambertini: Yeah. Thanks a lot, Dr. Pal. Receiving this compliment from you is fantastic. So, thanks a lot for that. From my side, in terms of my research, I've been interested in the field of breast cancer in young women since the start of my training. I've had very good mentors from Italy, from Europe, from the U.S. I'm still interested in this field, so I think we still have a lot to learn to try to improve the care of young women with breast cancer. For example, the oncofertility care, which is something I worked a lot over the past years. Now with all the new treatment options, there's a sort of new chapter of oncofertility counseling. So, what's the impact of immunotherapy? What's the impact of the new targeted agents?  More on the genetic aspects, now we know that there's not only BRCA1 or BRCA2. There are a lot of other different genes that may increase the risk of breast cancer and other malignancies. And also for these genes, we really don't have a lot of evidence to counsel women on prognosis, treatment, prevention strategy. So we need to learn way more for this special patient population that are quite rare, and so we really need a multicenter academic effort to try to give some evidence in this field. Dr. Monty Pal: Yeah. It's tough because these are rare circumstances, but, you know, I think that you've done really well to sort of define some collective experiences that I think really define therapy. I mean, I just remember when I was in training 25 years ago, just reading through textbooks where all the experience around breast cancer and pregnancy was really just very sort of anecdotal almost, you know? And so it's great to see that the state of the science has moved forward.  Well, gosh, I really enjoyed our conversation today. I think your study really reminds us how powerful genetic information is in terms of improving outcomes. And, you know, hopefully this will lead some individuals to perhaps test more broadly in appropriate settings. So, thank you so much, Matteo, for joining us today with your fantastic insights on the ASCO Daily News Podcast. Dr. Matteo Lambertini: Thank you very much, Dr. Pal. It's a real pleasure. Dr. Monty Pal: And thanks to our listeners too. You'll find a link to Dr. Lambertini's study in the transcript of this episode. Finally, if you value the insights that you heard today on the ASCO Daily News Podcast, please rate, review, and subscribe wherever you get your podcasts. Thanks a ton. Disclaimer: The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement. Find out more about today's speakers:    Dr. Sumanta (Monty) Pal  @montypal  Dr. Matteo Lambertini @matteolambe   Follow ASCO on social media:     @ASCO on Twitter    ASCO on Bluesky   ASCO on Facebook     ASCO on LinkedIn     Disclosures:    Dr. Monty Pal:   Speakers' Bureau: MJH Life Sciences, IntrisiQ, Peerview  Research Funding (Inst.): Exelixis, Merck, Osel, Genentech, Crispr Therapeutics, Adicet Bio, ArsenalBio, Xencor, Miyarsian Pharmaceutical  Travel, Accommodations, Expenses: Crispr Therapeutics, Ipsen, Exelixis  Dr. Matteo Lambertini: Consulting or Advisory Role: Roche, Novartis, Lilly, AstraZeneca, Pfizer, MSD, Exact Sciences, Gilead Sciences, Seagen, Menarini, Nordic Pharma Speakers' Bureau: Takeda, Roche, Lilly, Novartis, Pfizer, Sandoz, Ipsen, Knight Therapeutics, Libbs, Daiichi Sankyo, Gilead Sciences, AstraZeneca, Menarini, AstraZeneca, Menarini Research Funding (Inst.): Gilead Sciences Travel, Accommodations, Expenses: Gilead Sciences, Daiichi Sankyo Europe GmbH, Roche

EYE OF THE STORM SANDOZ 09.26.25 | VISLA FM by VISLA

===== MDJ Script/ Top Stories for September 12th Publish Date:  September 12th    Commercial: From the BG AD Group Studio, Welcome to the Marietta Daily Journal Podcast.    Today is Friday, September 12th and Happy Birthday to Jesse Owens I’m Keith Ippolito and here are the stories Cobb is talking about, presented by Times Journal Golfers tee off for a cause at 27th Alexis Grubbs Memorial Tournament Cobb OKs additional funding for South Cobb Library Expansion Cobb opts to settle with Purdue Pharma, Sacklers and other opioid manufacturers Plus, Leah McGrath from Ingles Markets on fast food All of this and more is coming up on the Marietta Daily Journal Podcast, and if you are looking for community news, we encourage you to listen and subscribe!  BREAK: Ingles Markets 10 STORY 1: Golfers tee off for a cause at 27th Alexis Grubbs Memorial Tournament This week, the 27th annual Alexis Grubbs Memorial Scholarship Golf Tournament teed off at Brookstone Country Club, bringing together over 100 golfers, sponsors, and volunteers for a day of camaraderie and purpose. Players grabbed gift bags (thanks to A 2nd Chance Bail Bonds), fueled up on Chick-fil-A biscuits, and hit the course after opening remarks from Carlos Rodriguez, the tournament chair. By 10:30 a.m., the Shotgun Start was underway. The event honors Alexis Grubbs, a Marietta High senior tragically lost in 1998, and has since awarded over $500,000 in scholarships to students pursuing legal careers. Winners? Matthew Enslein, Aaron Tomlinson, David Lyles, and Scott Lawrence. STORY 2: Cobb OKs additional funding for South Cobb Library Expansion  This week, the Cobb County Board of Commissioners greenlit $500,000 in extra funding to expand the South Cobb Regional Library by 5,000 square feet. Commissioner Monique Sheffield, who’s been pushing for this since 2021, said the project will be a game-changer for the community. The library, which opened in 2006, is one of the busiest in the county—especially for computer use. The expansion will add a new community space, a bigger teen area, and a computer lab, addressing a critical need for internet access in the area. Other board approvals? Speed signs, road projects, and grants for workforce programs. STORY 3: Cobb opts to settle with Purdue Pharma, Sacklers and other opioid manufacturers   The Cobb County Board of Commissioners has signed off on three new opioid settlements, but not without some debate. The vote was 3-1, with Commissioner Keli Gambrill opposing and Erick Allen absent. The settlements include payouts from Purdue Pharma, the Sackler family, and eight other manufacturers, all tied to their role in fueling the opioid epidemic. Cobb could see nearly $1 million from Sandoz alone, with funds earmarked for addiction treatment, prevention, and education. We have opportunities for sponsors to get great engagement on these shows. Call 770.799.6810 for more info.  We’ll be right back. Break: COBB MAKE A WISH STORY 4: 'Our city is strong': Mableton holds inaugural State of the City address With dancers, a marching band, and a crowd of hundreds, Mayor Michael Owens delivered Mableton’s first-ever State of the City address, blending optimism with a dose of realism. “The state of our city is strong,” Owens declared, but he didn’t shy away from the challenges. Roads, bridges, infrastructure—there’s work to do. Still, he painted a vision of a diverse, united, and thriving Mableton, calling it “not just another Atlanta suburb” but a cultural destination. Owens highlighted the city’s $13 million budget—no property taxes yet—and plans for affordable housing, smart growth, and a pedestrian-friendly future. STORY 5: OUT AND ABOUT: 5 things to do this weekend in Cobb County — Sept. 12 - 14 Fright Fest at Six Flags Ready to scream? Six Flags Over Georgia’s Fright Fest is back, running select nights through Nov. 2. Starting at 6 p.m., you can wander haunted mazes, dodge scare zones, catch creepy live shows, and ride coasters in the dark. Tickets? $69 for all-day access or $35 if you’re just here for the haunted mazes. Marietta Artisan Market Saturday morning plans? Head to downtown Marietta for the weekly artisan market on Mill Street, 9 a.m. to 1 p.m. Over 35 artists will be there, including this week’s spotlight: Jess Hain, who crafts stunning sterling silver jewelry and stained glass sun catchers. Coffee, Campfire, and Cryptids Friday night, grab some cocoa and dive into Marietta’s spookiest legends at Coffee, Campfire, and Cryptids in Atherton Square. Wendigos, mysterious creatures, and folklore-inspired goodies await. Starts at 6 p.m. Comedy on the Square Need a laugh? The Alley Stage’s “Comedy on the Square” show hits Friday and Saturday at 8 p.m. Tickets start at $27—grab them online or at the door. Dog Days at Smith-Gilbert Gardens Bring your pup to Smith-Gilbert Gardens this Saturday, 9 a.m. to 4 p.m., for a stroll through 18 acres of greenspace. Admission’s just $3. And now here is Leah McGrath from Ingles Markets on fast food We’ll have closing comments after this. Break: Ingles Markets 10 Signoff-   Thanks again for hanging out with us on today’s Marietta Daily Journal Podcast. If you enjoy these shows, we encourage you to check out our other offerings, like the Cherokee Tribune Ledger Podcast, the Marietta Daily Journal, or the Community Podcast for Rockdale Newton and Morgan Counties. Read more about all our stories and get other great content at mdjonline.com Did you know over 50% of Americans listen to podcasts weekly? Giving you important news about our community and telling great stories are what we do. Make sure you join us for our next episode and be sure to share this podcast on social media with your friends and family. Add us to your Alexa Flash Briefing or your Google Home Briefing and be sure to like, follow, and subscribe wherever you get your podcasts. Produced by the BG Podcast Network Show Sponsors: www.ingles-markets.com Cobb Make a Wish #NewsPodcast #CurrentEvents #TopHeadlines #BreakingNews #PodcastDiscussion #PodcastNews #InDepthAnalysis #NewsAnalysis #PodcastTrending #WorldNews #LocalNews #GlobalNews #PodcastInsights #NewsBrief #PodcastUpdate #NewsRoundup #WeeklyNews #DailyNews #PodcastInterviews #HotTopics #PodcastOpinions #InvestigativeJournalism #BehindTheHeadlines #PodcastMedia #NewsStories #PodcastReports #JournalismMatters #PodcastPerspectives #NewsCommentary #PodcastListeners #NewsPodcastCommunity #NewsSource #PodcastCuration #WorldAffairs #PodcastUpdates #AudioNews #PodcastJournalism #EmergingStories #NewsFlash #PodcastConversations See omnystudio.com/listener for privacy information.

From the BBC World Service: The pharmaceutical industry is still waiting to see what duties they'll be hit with, but pharma giant Sandoz, based in Switzerland, says the duties won't get them to move manufacturing to the U.S. Then, President Donald Trump called for the boss of U.S. chipmaker Intel to resign. And, the Congolese government is in the spotlight for spending massive amounts of money to sponsor some of the world's biggest soccer teams.

From the BBC World Service: The pharmaceutical industry is still waiting to see what duties they'll be hit with, but pharma giant Sandoz, based in Switzerland, says the duties won't get them to move manufacturing to the U.S. Then, President Donald Trump called for the boss of U.S. chipmaker Intel to resign. And, the Congolese government is in the spotlight for spending massive amounts of money to sponsor some of the world's biggest soccer teams.

Felicity Hannah speaks to Richard Saynor, CEO of pharmaceutical giant Sandoz, about the impact of US tariffs. And we look at the latest booking trends with staycations.

Earlier this month, President Donald Trump announced the U.S. would impose up to a 200% tariff on imported pharmaceuticals, though he would give them up to a year and a half before fully implementing the tariffs. Trump's goal is to bring more manufacturing to the United States, but one pharmaceutical CEO, Richard Saynor of Sandoz, says there is little incentive to build in the U.S. Jessica Mendoza hosts. Further Listening:- Why Trump Pushed His Tariff Deadline - Inside the Surprise U.S.-China Trade Deal  Sign up for WSJ's free What's News newsletter. Learn more about your ad choices. Visit megaphone.fm/adchoices

Even the most advanced medicine becomes meaningless if patients can't access or afford it.So what is healthcare truly innovating for — technological breakthroughs, or the basic human right to live? As treatment costs rise, supply chains remain fragile, and quality varies, Vietnam's healthcare system faces a complex balancing act: affordability, quality, and reliability. Can we achieve all three, or must we accept trade-offs?In this week's Vietnam Innovators (English edition), we dive into the current landscape, opportunities, and challenges shaping Vietnam's healthcare sector. Our guest, Charaf Eddine Kadri, Country Head of Sandoz Vietnam, brings over 18 years of pharmaceutical leadership experience across Asia, Europe, Africa, and the Middle East — offering a sharp, global perspective on innovation in healthcare and the evolving pharmaceutical market.Listen to this episode on YoutubeAnd explore many amazing articles about the pioneers at: https://vietcetera.com/vn/bo-suu-tap/vietnam-innovatorFeel free to leave any questions or invitations for business cooperation at hello@vni-digest.com

In this episode, Rick speaks with Joy Sandoz, a multi-location Alloy franchisee known for her excellent community-building practices.With a background that spans graphic production to personal training and business ownership, Joy shares some tips on how to create a gym where members feel like family.She shares how the simple things – from knowing everyone's names to hosting fun events – make a huge difference in member retention.Rick and Joy also discuss the importance of leadership and developing soft skills to lead teams effectively. Joy has empowered her staff to grow by teaching them the ins and outs of the business while creating an inclusive, growth-focused culture.Joy's tips for anyone looking to get into the fitness franchise business? Lean into your soft skills and be authentic. Listen in to hear more!Key TakeawaysIntro (00:00)Joy's shift from a non-athletic background to fitness (02:27)Importance of community in gym culture (05:59)Creating a gym atmosphere where people want to hang out (08:04)Building a team that feels like family (15:18)Continuous learning for personal and team growth (18:33)Developing leadership by teaching team independence (23:40)Additional Resources:- Joy's Instagram: https://www.instagram.com/mappchik- Alloy Personal Training- Learn About The Alloy Franchise Opportunity---------You can find the podcast on Apple, Google, Spotify, Stitcher, or wherever you listen to podcasts.If you haven't already, please rate and review the podcast on Apple Podcasts!

Current developments, such as most favored nation (MFN) pricing, grabbed much of the spotlight when key industry stakeholders met in Philadelphia for the Pricing and Contracting USA Conference. In this episode of Connected With Latham, Allan Thoen, Director & Associate General Counsel with Sandoz, joins Washington, D.C. partner Chris Schott and associate Danny Machado to discuss impressions and takeaways from the conference. And read our bi-weekly Drug Pricing Digest on the website or subscribe to receive future editions in your inbox.   This podcast is provided as a service of Latham & Watkins LLP. Listening to this podcast does not create an attorney client relationship between you and Latham & Watkins LLP, and you should not send confidential information to Latham & Watkins LLP. While we make every effort to assure that the content of this podcast is accurate, comprehensive, and current, we do not warrant or guarantee any of those things and you may not rely on this podcast as a substitute for legal research and/or consulting a qualified attorney. Listening to this podcast is not a substitute for engaging a lawyer to advise on your individual needs. Should you require legal advice on the issues covered in this podcast, please consult a qualified attorney. Under New York's Code of Professional Responsibility, portions of this communication contain attorney advertising. Prior results do not guarantee a similar outcome. Results depend upon a variety of factors unique to each representation. Please direct all inquiries regarding the conduct of Latham and Watkins attorneys under New York's Disciplinary Rules to Latham & Watkins LLP, 1271 Avenue of the Americas, New York, NY 10020, Phone: 1.212.906.1200

This special episode formed part of FP&A Con 2025 which saw a record-breaking 1500 registrants.  The guests: Nathan Bell, Managing Partner, VAi Consulting, is among the most in-demand experts. Bell has unique experience– having started in computer science, before leading finance teams at Native American Bank, Digital Media Trends and Gartner– where he advised hundreds of FP&A teams facing chaotic data situations). Anna Tioma former CFO of Sandoz and  Softeq. Most recently she has pivoted to become a fractional CFO at Blend2Balance.  Anna Yamashita, Solutions Consulting at Data Rails who has worked across SAS finance throughout her career where she helps FP&A teams implement modern performance management solutions. In this session:  How AI is being applied in real FP&A workflows today  Predictive analytics as the gold standard Getting to a single version of truth with AI  ROI in AI  Mastering Data Management  Misconceptions about AI in finance and security  Co-pilot, prompts Bonus: Security and AI 

Dans cette saison, pas de meurtre mais un récit d'emprise familiale. Dans des immeubles du XIe, XIIe et XXe arrondissements, une étrange communauté s'épanouit depuis plus de deux cent ans. Ce n'est pas vraiment une secte mais plutôt une organisation secrète, une société dans la société, comparable à aucune autre. Tout au long des 4 épisodes, Caroline Nogueras est accompagnée de la journaliste Suzanne Privat, autrice du livre La Famille, itinéraire d'un secret paru aux éditions Points. Mon oncle Auguste La famille se réunit autour d'une chrétienté en marge de l'Eglise, régi par l'austérité et la discrétion. Depuis sa création en 1819, d'autres patronymes sont venus grossir les rangs. Les Havet et Thibout ont été rejoints par les Sanglier, Déchelette, Sandoz, Maître, Pulin et Fert. Au début du XXeme siècle, un homme, Paul Augustin Thibout, descendant direct des fondateurs, va durcir le ton et cadrer les troupes. Découvrez la dernière saison : ⁠⁠⁠⁠⁠⁠⁠⁠L'énigme de l'ange de l'A10⁠ Un podcast Bababam Originals Ecriture : Capucine Lebot Voix : Caroline Nogueras En partenariat avec upday.  Première diffusion : 5 octobre 2023 Learn more about your ad choices. Visit megaphone.fm/adchoices

In der heutigen Folge sprechen die Finanzjournalisten Anja Ettel und Holger Zschäpitz über Nvidias neuen KI-Billigchip, Hoffen auf das Pharma-Revival und was diese Woche sonst noch wichtig wird. Außerdem geht es um VanEck Uranium and Nuclear Technologies ETF (WKN: A3D47K), Uranium Energy, Oklo, Nuscale, Health Care Select Sector SPDR (WKN: A14QB2), CVS Health, United Health Group, Eli Lilly, Cigna, Danaher, Thermo Fisher Scientific sowie Gilead, Sandoz, J&J, Roche, Sanofi, VanEck Quantum Computing ETF (WKN: A418QM) Google, IBM, Microsoft, Sony, Boeing, Honeywell, IonQ, Rigetti und D-Wave. Wir freuen uns an Feedback über aaa@welt.de. Noch mehr "Alles auf Aktien" findet Ihr bei WELTplus und Apple Podcasts – inklusive aller Artikel der Hosts und AAA-Newsletter.[ Hier bei WELT.](https://www.welt.de/podcasts/alles-auf-aktien/plus247399208/Boersen-Podcast-AAA-Bonus-Folgen-Jede-Woche-noch-mehr-Antworten-auf-Eure-Boersen-Fragen.html.) [Hier] (https://open.spotify.com/playlist/6zxjyJpTMunyYCY6F7vHK1?si=8f6cTnkEQnmSrlMU8Vo6uQ) findest Du die Samstagsfolgen Klassiker-Playlist auf Spotify! Disclaimer: Die im Podcast besprochenen Aktien und Fonds stellen keine spezifischen Kauf- oder Anlage-Empfehlungen dar. Die Moderatoren und der Verlag haften nicht für etwaige Verluste, die aufgrund der Umsetzung der Gedanken oder Ideen entstehen. Hörtipps: Für alle, die noch mehr wissen wollen: Holger Zschäpitz können Sie jede Woche im Finanz- und Wirtschaftspodcast "Deffner&Zschäpitz" hören. Außerdem bei WELT: Im werktäglichen Podcast „Das bringt der Tag“ geben wir Ihnen im Gespräch mit WELT-Experten die wichtigsten Hintergrundinformationen zu einem politischen Top-Thema des Tages. +++ Werbung +++ Du möchtest mehr über unsere Werbepartner erfahren? [**Hier findest du alle Infos & Rabatte!**](https://linktr.ee/alles_auf_aktien) Impressum: https://www.welt.de/services/article7893735/Impressum.html Datenschutz: https://www.welt.de/services/article157550705/Datenschutzerklaerung-WELT-DIGITAL.html

Thank you for joining us. Many customers seek our Million Marker's services to help balance their hormones in hopes of improving their chances of conceiving. Bringing a child into this world is rewarding, but it's also a lot of hard work. Being a new mom brings a whole new world of stress that we've never experienced before. Thankfully, there are some things we can do to help make stress management a bit easier. That's why we're so excited to be joined today by Elizabeth Joy Sandoz. Elizabeth Joy is a birth doula and prenatal coach. Plus, she is the host of the Miraculous Mamas podcast. Today, we're going to talk about managing stress as a new parent.Learn more about Elizabeth's services: https://elizabethjoy.co/Get tested for BPA, phthalates, parabens, and other hormone-disrupting chemicals with Million Marker's Detect & Detox Test Kit: https://www.millionmarker.com/

This Day in Legal History: President Lincoln DiesOn this day in legal history, April 15, 1865, President Abraham Lincoln died from a gunshot wound inflicted the night before by actor and Confederate sympathizer John Wilkes Booth. The assassination occurred at Ford's Theatre in Washington, D.C., where Lincoln was watching a play with his wife. He was shot in the back of the head and never regained consciousness, dying the next morning at 7:22 a.m. His death was the first assassination of a U.S. president and triggered a constitutional transition of power during a critical moment in American history. Vice President Andrew Johnson was sworn in the same day, inheriting the enormous task of leading the country through the fragile early stages of Reconstruction.Legally, Lincoln's assassination set several precedents. It led to the use of military tribunals to try civilians involved in Booth's conspiracy, a decision that remains controversial in constitutional law. The event also underscored the importance of presidential succession, later clarified by the 25th Amendment. In the immediate aftermath, martial law and curfews were imposed in the capital, and a massive manhunt ensued for Booth and his co-conspirators. The killing intensified public sentiment against the South and complicated efforts to reunify the nation. Johnson's approach to Reconstruction diverged sharply from Lincoln's more conciliatory plans, shaping decades of legal and political conflict over civil rights. The assassination deeply impacted how the federal government approached both national security and executive protection. The tragedy marked not just the loss of a president, but a shift in the legal and political structure of post-Civil War America.As Lincoln's funeral train retraced the route that had carried him from obscurity in Illinois to the presidency, it served as a symbolic farewell to both the man and the future he might have shaped. Each stop along the way—cities draped in mourning, crowds in silent grief—marked not only the end of his political journey but also the shunting off of a potential trajectory for his second term. Had Lincoln lived, his vision for a more lenient and reconciliatory Reconstruction might have softened the bitter divisions that would later deepen under Andrew Johnson's combative leadership. Perhaps civil rights protections would have been implemented sooner, with Lincoln using his political capital and moral authority to push for more lasting equality. The possibility remains that a different course could have been taken—one that prioritized unity without compromising justice, and that may have led to a more inclusive and less violent post-war America.Kilmar Abrego Garcia, a legally residing Salvadoran migrant in Maryland with a U.S. work permit, was wrongly deported to El Salvador in March, despite a judge's order blocking his removal. The Trump administration acknowledged the deportation was in error but has told a federal court it is not obligated to help him return from prison in El Salvador, interpreting a Supreme Court directive to "facilitate" his return as limited to removing domestic barriers—not assisting with his release abroad. A U.S. District Court judge had ordered the government to bring him back, a decision the Supreme Court upheld by rejecting the administration's appeal. However, a top immigration official has now argued the deportation order is moot, citing Abrego Garcia's alleged ties to MS-13, a group newly designated as a foreign terrorist organization. The State Department has confirmed that Abrego Garcia is "alive and secure" in a terrorism detention facility in El Salvador. Legal efforts continue, with Abrego Garcia's attorneys seeking more information from the government. The administration warns this could disrupt diplomatic talks, particularly with El Salvador's President Nayib Bukele visiting Washington. President Trump has said his administration would comply if ordered directly by the Supreme Court.Trump administration says it is not required to help wrongly deported man return to US | ReutersSandoz, a Swiss generic drugmaker, has filed a U.S. antitrust lawsuit against Amgen, accusing it of unlawfully maintaining a monopoly on its arthritis drug Enbrel. The lawsuit, filed in federal court in Norfolk, Virginia, alleges that Amgen created a "thicket of patents" to block the entry of biosimilar competitors like Sandoz's Erelzi, which has been approved by the FDA since 2016 but has not launched in the U.S. Sandoz claims this strategy has kept its lower-cost alternative off the market, depriving patients of affordable options and causing the company to lose millions in potential monthly sales. Amgen has not yet commented on the lawsuit. Enbrel generated $3.3 billion in U.S. revenue in 2024 alone and is used to treat inflammatory diseases such as rheumatoid arthritis. Sandoz argues that Amgen's patent practices violate federal antitrust laws by suppressing competition and artificially extending its market dominance. The company is seeking an injunction to stop Amgen from using its patent portfolio in this way, as well as financial damages for lost sales.Sandoz files U.S. antitrust lawsuit against Amgen over arthritis drug | ReutersThe U.S. Government Accountability Office (GAO) has agreed to investigate recent changes at the Securities and Exchange Commission (SEC), including those influenced by the White House and the Department of Government Efficiency (DGE), led by Elon Musk. This probe follows a request from Senators Elizabeth Warren and Mark Warner, who raised concerns about the SEC's ability to fulfill its regulatory duties amid sweeping restructuring efforts. Since President Trump's return to office and the Republican takeover of the agency, the SEC has reduced staff, ended leases, and reorganized operations. It has also scaled back enforcement efforts and seen a wave of resignations as part of a broader federal downsizing initiative. The GAO confirmed that the request for an investigation falls within its authority, with the review expected to begin in about three months. Lawmakers stress the importance of understanding how these changes may be undermining the SEC's mission. The agency's funding, while approved by Congress, is sourced from transaction fees rather than taxpayer dollars. These developments coincide with market instability triggered by Trump's recent tariff announcement.US congressional watchdog to probe changes at the SEC, letter says | Reuters This is a public episode. If you'd like to discuss this with other subscribers or get access to bonus episodes, visit www.minimumcomp.com/subscribe

In this episode of The Psychedelic Podcast, Paul F. Austin welcomes New York Times bestselling author Norman Ohler. Find full show notes and links here: https://thethirdwave.co/podcast/episode-297/?ref=278 Norman shares his deep research into the hidden history of LSD, revealing the untold connections between Arthur Stoll (CEO of Sandoz), Nazi Germany, and the CIA's MKUltra program. He explains how LSD's development as a mental health medicine was derailed by intelligence agencies seeking a "truth drug" for interrogations, and how the substance traveled from Swiss laboratories to Nazi concentration camps and eventually to American universities. Norman also discusses his personal connection to psychedelics through his mother's Alzheimer's treatment with microdosing, and offers thoughtful reflections on the current psychedelic renaissance. Norman Ohler is one of Germany's best living writers: a New York Times Bestselling author, translated into over 30 languages. His books include "Blitzed", "The Bohemians", and "Tripped". He has 2 children and lives in Berlin. Highlights: Welcome & introduction Who is Arthur Stoll, the grandfather of psychedelics? The Nazi Germany and LSD connection Albert Hoffman's complicated relationship with LSD The pharmaceutical politics behind psychedelic suppression Reflections on the modern psychedelic renaissance The challenges of psychedelics in a globalized society From "Blitzed" to "Tripped": Norman's research journey Norman's personal connection: Microdosing for Alzheimer's The mysterious story of JFK and LSD Episode Links: Website Instagram: @normanohler Norman's book "Tripped: Nazi Germany, the CIA and the Dawn of the Psychedelic Age" Norman's previous book "Blitzed: Drugs in the Third Reich" Rise and Fall of the Third Reich" by William Shirer These show links may contain affiliate links. Third Wave receives a small percentage of the product price if you purchase through the above affiliate links.

Il y a 80 ans, le chimiste Albert Hofmann enfourchait son vélo pour une folle cavalcade à travers Bâle, imprégné volontairement et surpris par la substance qu'il était parvenu à synthétiser quelques années plus tôt : le LSD. Il était alors loin de se douter que cette drogue psychédélique, capable de soulager certaines maladies psychiques, allait devenir, avec l'aide d'anciens chimistes nazis, un objet de recherche militaire et un outil de contrôle mental utilisé par la CIA pendant la Guerre froide. Loin également d'imaginer que le LSD allait non pas déferler sur le marché du médicament grâce à sa firme Sandoz, mais accéder à la notoriété grâce au mouvement psychédélique et aux milieux artistiques et intellectuels des années 60. En 1966, il est interdit et retombe finalement dans la clandestinité. Aujourd'hui la recherche montre un intérêt renouvelé pour le potentiel thérapeutique des substances psychédéliques comme le LSD. Daniele Zullino est psychiatre et médecin chef du service d'addictologie des Hôpitaux universitaires de Genève, il est au micro de Céline Roduit pour Histoire Vivante.

Chapter 1 What's Cheyenne Autumn by Mari Sandoz"Cheyenne Autumn" is a historical novel by Mari Sandoz, published in 1953. The book recounts the Cheyenne tribe's harrowing journey in 1878, as they attempted to return to their homeland in Wyoming after being forcibly relocated to reservations in Oklahoma. Through rich, evocative prose, Sandoz explores the themes of displacement, resilience, and the struggle for identity amidst the overwhelming forces of American expansionism.The narrative highlights key figures such as Chief Dull Knife and the challenges faced by the Cheyenne, including hunger, illness, and the brutal realities of life on the plains. Sandoz's empathetic portrayal gives voice to the Cheyenne people, shedding light on their culture, traditions, and the deep impact of colonization. The novel serves as both a poignant historical account and a reflection on the enduring spirit of a proud people.Chapter 2 Cheyenne Autumn by Mari Sandoz Summary"Cheyenne Autumn" by Mari Sandoz is a historical novel that vividly recounts the experiences of the Cheyenne people during the 1870s, focusing on their struggles and resilience in the face of westward expansion and U.S. government policies. The narrative primarily follows the Cheyenne tribe, particularly highlighting the journey and hardships faced by a group of Cheyenne led by a chief named Little Wolf as they seek to return to their homeland after being relocated to a barren reservation in Oklahoma. Central to the story is the theme of survival and the deep connection the Cheyenne have to their land, culture, and identity. The characters are depicted with depth, showcasing their traditions, spirituality, and the bonds of community amidst the suffering caused by violence, starvation, and broken treaties.The novel also explores the conflict between the U.S. government and Native American tribes, illustrating the injustices perpetrated against the Cheyenne. As the story unfolds, readers experience the courage and determination of the Cheyenne as they undertake the perilous journey northward, battling not just the elements but also their own disillusionment and trauma.Through rich descriptions and a blend of historical fact and fiction, Sandoz emphasizes the plight of the Cheyenne and other Native American tribes, making the narrative a powerful commentary on the impact of colonization and the importance of cultural preservation.Chapter 3 Cheyenne Autumn AuthorMari Sandoz was an American author born on May 11, 1896, in Warren, Nebraska, and she passed away on March 10, 1966. She is best known for her works that capture the history and experiences of the Great Plains, particularly in relation to Native Americans and early settlers. Cheyenne AutumnSandoz released Cheyenne Autumn in 1953. This historical novel focuses on the Cheyenne people's struggles and the forced relocation they faced, depicting both the Cheyenne and the American government's perspectives. It stands as a notable commentary on the injustices faced by Native Americans and reflects Sandoz's commitment to understanding and portraying their culture. Other Notable WorksMari Sandoz wrote several other books, including:Son of the Gamblin' Man (1945)Old Jules (1935) This semi-autobiographical work about her father is one of her most acclaimed books.The Battle of the Rosebud (1944) A historical novel about the battle involving Crazy Horse.The Cattlemen: From the Rio Grande to Montana (1941) A comprehensive account of the cattle ranching industry.The Horse and the Plains Indians (1955) A notable work highlighting the relationship between Native Americans and horses. Best EditionDetermining the "best" edition can vary based on personal preference—some readers prefer the original texts for their authenticity, while others prefer updated editions with additional...

Redefining Sales Outreach with Gifting In this episode, Kris Rudeegraap explains how Sendoso uses AI and data to personalize gifting and revolutionize customer engagement. From streamlining logistics to automating gifting actions, Sandoz empowers teams to stand out in sales. Explore tips for leveraging gifting at every touchpoint to drive results and foster lasting connections

Today's episode delves into rehumanizing work within organizations, featuring our esteemed guest Frank Kellenberg, the Global Head of Culture and Inclusion at Sandoz. With over 20 years of leadership experience in international HR roles for companies like Hewlett Packard, Siemens, and Adidas, Frank brings a wealth of knowledge on leadership development, talent management, and the critical role of diversity, equity, and inclusion (DEI) in fostering a thriving company culture.In this episode, Frank shares:His perspectives on the importance of human connections in a technology-driven workplaceThe necessity of open and authentic communication from leadersThe challenges of adapting to different cultural environmentsHow Sandoz, a global leader in generic and biosimilar medicines, is navigating its cultural transformation post-independence from NovartisThe human leadership model, emphasizing trust, self-determination, and growthStrategies for implementing effective leadership training programs.We also touch on the future of work and the essential skills of empathy and communication in an increasingly automated world. Join us as we uncover practical insights to help leaders build human-centric workplaces where every employee feels valued and connected.Frank Kellenberg has more than 20 years of leadership experience in various operational and strategic HR roles in international companies, including Hewlett Packard, Siemens, Ingram Micro, adidas, and Novartis.Having worked for global organizations across Europe, Frank Kellenberg built his experience in culture, D&I, leadership development, talent management and organization development. He has a passion to drive innovation & change to help people & organizations to transform themselves to achieve goals. At the same time, he combines strategic and people-oriented thinking with a focus on operational excellence.Frank has an MBA in Business Psychology and also holds a Master's Degree in Adult Education.Connect with Andy Storch here:WebsiteLinkedInJoin us in the Talent Development Think Tank Community!Connect with Frank Kellenberg:LinkedInWebsite